Histochemical Staining for EGFR Ligand Spatial Mapping
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for evaluating EGFR protein expression and EGFR ligand expression in colorectal tumors are inadequate in predicting response to anti-EGFR therapies, as they fail to account for spatial relationships between EGFR and its ligands, leading to mixed results and variable treatment outcomes.
Innovation Solution
A histochemical staining methodology that involves obtaining and evaluating digital images of colorectal tumor sections stained for EGFR and its ligands, such as AREG and EREG, to assess expression patterns and spatial relationships, allowing for stratification of patients likely to respond to anti-EGFR therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If PCR-based detection systems are used to detect EGFR ligands, then ligand expression can be identified, but spatial relationships between ligands and receptors cannot be determined
Solution Approach 1:
The patent divides the detection process into separate staining steps for different targets (EGFR and EGFR ligands), with each step optimized for detecting specific molecules while preserving spatial information in the tissue architecture
Solution Approach 2:
The patent transitions from one-dimensional molecular detection (PCR) to two-dimensional spatial mapping by staining tissue sections and visualizing the physical locations of EGFR and its ligands relative to each other in the tissue context
2Measurement precision
If immunohistochemical analysis is performed on EGFR ligands, then ligand expression can be visualized, but clear correlation with therapy response is not achieved due to mixed results
Solution Approach 1:
The patent examines expression patterns at the local level within specific tissue regions, analyzing the relationship between EGFR and ligand expression in the same spatial context rather than averaging across entire samples
Solution Approach 2:
The patent combines detection of multiple targets (EGFR and multiple EGFR ligands) in the same tissue section to simultaneously assess both receptor and ligand expression patterns and their spatial relationships
3Ease of manufacture
If conventional staining methods are used, then individual markers can be detected, but simultaneous evaluation of multiple EGFR ligands and their spatial relationships is not possible
Solution Approach 1:
The patent develops a universal staining platform that can detect multiple different EGFR ligands (AREG, EREG, HB-EGF, TGFα) using the same methodological approach and tissue section format
Solution Approach 2:
The patent uses sequential staining approaches where different ligand-specific antibodies are applied to replicate sections of the same tissue block, allowing comparison of multiple ligand expressions while preserving the original tissue architecture
Data Source
AI summary
Methods and systems for predictive measures of anti-EGFR therapy response in wild type RAS/EGFR+ samples, e.g., histochemical staining methods for staining EGFR, AREG, and EREG, digital analysis of stained slides, and scoring algorithms that allow prediction of a response to anti-EGFR therapies. Analysis of the stained slides and scoring algorithms may include but are not limited to: a percent tumor cell positivity, computerized clustering algorithms, area density (e.g., area of tumor positive for one or more markers over total tumor area), average intensity (e.g., computerized methodology measuring average gray scale pixel intensity), average intensity broken down according to membrane, cytoplasmic, or punctate staining patterns), or any other appropriate parameter or combination of parameters. The methods of the present invention allow for resolving spatial expression patterns of the ligands and the receptor to determine what patterns are predictive for response to anti-EGFR therapies.